Hedge fund wins on Pozen buy
Tuesday, April 22, 2008 : PermalinkBizjournals.com- A Massachusetts hedge fund that rolled a bet on biotech company Pozen has seen it pay off in a big way.
PAR Capital Management says in Securities and Exchange Commission documents that its stake in Chapel Hill-based Pozen (Nasdaq: POZN) was 5.01 percent as of April 14. PAR owned 857,585 shares of Pozen as of Dec. 31, 2007, regulatory documents say. As of April 14, its stake had been raised to 1,489,996 shares.
The hedge fund crossed the 5 percent threshold just two days before the U.S. Food and Drug Administration was set to make a decision on whether Pozen’s migraine drug, Treximet, could be sold in the U.S. Investors are required to file ownership statements when they gain more than 5 percent ownership in a company.
More on this topic
(What's this?)
Hedge Fund 2009 Performance Numbers
(market folly, 1/14/10)
Steven Cohen's Hedge Fund SAC Capital: Portfolio Update
(market folly, 1/18/10)
GURU OUTLOOK: DAVID TEPPER – 2009′S BILLION DOLLAR MAN
(THE PRAGMATIC CAPITALIST, 12/23/09)
(POZN) Pozen Initiates New Phase III Trial
(Stock Blog Hub, 11/20/09)